Ozempic Market to Surpass USD 61.92 Billion by 2035 as GLP-1 Therapies Transform Diabetes and Obesity Care | SNS Insider
Austin, May 05, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Ozempic Market size was valued at USD 23.18 Billion in 2025 and is expected to reach USD 61.92 Billion by 2035, growing at a CAGR of 10.43% during the forecast period 2026–2035.
The global Ozempic market is witnessing strong growth on the back of increasing number and prevalence across the world. Key factors driving the growth of GLP-1 receptor agonists market include increasing adoption for management of weight, widening use as a treatment option for cardiovascular risk reduction and preference towards oral formulations as well injectable are also spurring market progress. Moreover, the growth in demand from healthcare systems is further supplemented by supportive reimbursement frameworks and an escalating awareness toward lifestyle diseases across the globe.
Get a Sample Report of Ozempic Market Forecast @ https://www.snsinsider.com/sample-request/10037
Ozempic Market Size and Forecast:
According to research insights, the Ozempic Market in the U.S. was valued at USD 9.03 Billion in 2025 and is expected to reach USD 23.94 Billion by 2035 growing at a CAGR of 11.45% over the next decade (2026–2035).
The United States accounts for the vast majority of global Ozempic sales based on the high prevalence of Type 2 diabetes and obesity, potent healthcare infrastructure, and early adoption of GLP-1s for diabetes control and weight loss.
Rising Prevalence of Type 2 Diabetes and Obesity to Drive Market Growth Globally
The main growth factor responsible for the growth of the Ozempic market is rising global burden of type 2 diabetes and obesity. GLP-1 receptor agonists face strong and increasing demand for the management of long-term metabolic disease in millions of patients. The increasing urbanization and more sedentary lifestyle combined with the poor dietary habits lead to the expansion of patient population.
Continued awareness of the cardiovascular effects of Ozempic,along with new drug-delivery systems-oral and extended release-is expected to improve treatment adherenceand clinical benefit in developed and emerging markets.
Ozempic Market Segmentation Analysis:
By Therapeutic Application
Adult-Onset Diabetes dominated the market with a revenue share of 56.32% in 2025 due to its high global prevalence and strong clinical adoption. Non-Insulin-Dependent Diabetes is expected to register the fastest CAGR of 11.34% during 2026–2035, driven by early diagnosis and increasing preference for GLP-1 therapies.
By Drug Formulation / Delivery
Injectable formulations (Ozempic Pen) accounted for the largest share of 69.87% in 2025 due to ease of administration and strong physician preference. Extended-release formulations are anticipated to grow at the fastest CAGR of 13.80% over the forecast period due to improved patient compliance and reduced dosing frequency.
By Sales Channel
Direct sales to hospitals and clinics held the highest share of 34.67% in 2025 owing to strong institutional procurement systems. Online platforms are projected to grow at the fastest CAGR of 11.74%, supported by increasing digital healthcare adoption.
By Distribution Channel
Hospital pharmacies dominated with a 39.16% share in 2025 due to centralized drug dispensing systems. Online pharmacies are expected to witness the fastest CAGR of 11.89% during 2026–2035 due to convenience and rising e-commerce penetration.
For a Personalized Briefing with Our Industry Analysts, Connect Now @ https://www.snsinsider.com/request-analyst/10037
Ozempic Market Regional Insights:
North America dominated the global incretin-based diabetes therapeutics market with 42.04% revenue share in 2025, attributable to developed healthcare infrastructure, high adoption of incretin-mimetics including GLP-1 therapies and favorable reimbursement systems. The region is characterized by continuous innovation across drug formulations (oral and injectable) along with high levels of awareness in patients.
Asia Pacific is the fastest growing region with a CAGR of 11.94% followed by North America and Europe owing to increasing diabetes prevalence, rising healthcare expenditure and improving access to advanced therapeutics in countries such as India, China and Japan.
Europe remains stable with well-established healthcare systems, increasing awareness, and changing treatments for obesity and cardiovascular risk management GLP-1.
Latin America, Middle East & Africa are also growing at a slow to a moderate rate, mostly due to better access to healthcare and increased awareness related to increasing number of targets such as metabolic disorders or diseases.
Major Players Analysis Listed in the Ozempic Market Report:
Ozempic Market Recent Developments:
Purchase Single User PDF of Ozempic Market Report @ https://www.snsinsider.com/checkout/10037
Exclusive Sections of the Report (The USPs):
Ozempic Market Report Scope
Rising Demand for Ozempic Market Data, Our Full Report Trend Analysis @ https://www.snsinsider.com/reports/ozempic-market-10037
Other Related Report:
Type 2 Diabetes Market
Obesity Treatment Market
Anti-Obesity Drugs Market
GLP-1 Receptor Agonist Market
Insulin Delivery Devices Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.